Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military’s health insurance coverage, with no copay for average-risk individuals ages 45 and older.
Shield is the first and only blood test approved by the FDA as a primary screening option for CRC, offering U.S. military troops a more pleasant and convenient option for screening by overcoming barriers associated with other screening methods. According to the Department of Defense, there are approximately 1.3 million active-duty service members. Those above the age of 45 – along with their families of screening-eligible age – will now have access to Shield, the latest innovation in CRC screening.